Publication Name	World Journal of Gastroenterology
Manuscript ID	95617
Country	Portugal

Received	2024-04-14 12:13
Peer-Review Started	2024-04-14 12:13
To Make the First Decision
Return for Revision	2024-08-06 03:22
Revised	2024-08-10 13:57
Second Decision	2024-08-23 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-23 06:37
Articles in Press	2024-08-23 06:37
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-08-27 19:55
Typeset the Manuscript	2024-09-02 03:08
Publish the Manuscript Online	2024-09-10 09:27

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Real-world clinical efficacy of tofacitinib in moderate to severe ulcerative
Manuscript Source	Invited Manuscript
All Author List	Sara R Lopes, Claudio Martins, Madalena Teixeira and David Tomás
ORCID	Author(s) ORCID Number Sara R Lopes http://orcid.org/0009-0009-6207-7437 Claudio Martins http://orcid.org/0000-0002-0038-2833
Funding Agency and Grant Number
Corresponding Author	Claudio Martins, MD, Doctor, Doctor, Department of Gastroenterology, Unidade Local de Saúde da Arrábida-Hospital de São Bernardo, Rua Camilo Castelo Branco, Setúbal 2910-446, Portugal. cmartins1@campus.ul.pt
Key Words	Ulcerative colitis; Tofacitinib; Real-world studies; Inflammatory bowel disease; Janus kinase inhibitor
Core Tip	Tofacitinib, an oral small-molecule agent, has proven efficacy in inducing and maintaining remission among patients with moderate to severe ulcerative colitis. Real-world studies have showcased its effectiveness and safety profile for treating this condition, primarily within Western countries. There has been a limited number of studies conducted on Asian patients.
Publish Date	2024-09-10 09:27
Citation	<p>Lopes SR, Martins C, Teixeira M, Tomás D. Real-world clinical efficacy of tofacitinib in moderate to severe ulcerative. <i>World J Gastroenterol</i> 2024; 30(34): 3929-3931</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i34/3929.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i34.3929

Full Article (PDF)	WJG-30-3929-with-cover.pdf
Manuscript File	95617_Auto_Edited_025713.docx
Answering Reviewers	95617-answering-reviewers.pdf
Audio Core Tip	95617-audio.m4a
Conflict-of-Interest Disclosure Form	95617-conflict-of-interest-statement.pdf
Copyright License Agreement	95617-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	95617-non-native-speakers.pdf
Peer-review Report	95617-peer-reviews.pdf
Scientific Misconduct Check	95617-scientific-misconduct-check.png
Scientific Editor Work List	95617-scientific-editor-work-list.pdf
CrossCheck Report	95617-crosscheck-report.pdf